SIRT3 expression as a biomarker for better prognosis in gastric cancer

Kuo Hung Huang; Chia Chi Hsu; Wen Liang Fang; Chin Wen Chi; Ming Ta Sung; Hwa Li Kao; Anna Fen Yau Li; Pen Hui Yin; Muh Hwa Yang; Hsin Chen Lee

doi:10.1007/s00268-013-2359-0

SIRT3 expression as a biomarker for better prognosis in gastric cancer

Kuo Hung Huang, Chia Chi Hsu, Wen Liang Fang, Chin Wen Chi, Ming Ta Sung, Hwa Li Kao, Anna Fen Yau Li, Pen Hui Yin, Muh Hwa Yang^*, Hsin Chen Lee

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Background: SIRT3 - mitochondrial nicotinamide adenine dinucleotide- dependent deacetylase sirtuin-3 - plays an important role in regulating cell metabolism and carcinogenesis. The role of SIRT3 in gastric cancer has not yet been investigated. Methods: A total of 221 gastric cancer patients who underwent curative surgery were enrolled at the Department of Surgery, Taipei Veterans General Hospital. SIRT3 expression in gastric tissues and tumors were examined in these patients using immunohistochemical staining. Clinicopathologic characteristics and survival were analyzed and compared in gastric cancer patients with or without SIRT3 expression. Results: The 5-year survival rates of patients with or without SIRT3 expression were 51.2 and 39.1 %, respectively (p = 0.005). The 5-year disease-free survival rates of patients with or without SIRT3 expression were 49.6 and 38.0 %, respectively (p = 0.010). Microscopic features showed that there are more poor cell differentiation (p = 0.001), more diffuse-type Lauren's histology (p = 0.018), and more scirrhous-type stromal reactions (p = 0.027) in gastric cancer without SIRT expression. Multivariate analysis with overall survival as an endpoint showed that age (p < 0.001), Lauren's histology (p = 0.007), stromal reaction (p = 0.035), TNM pathologic N category (p < 0.001), and SIRT3 expression (p < 0.001) were significantly correlated with gastric cancer. Conclusions: Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer.

Original language	English
Pages (from-to)	910-917
Number of pages	8
Journal	World Journal of Surgery
Volume	38
Issue number	4
DOIs	https://doi.org/10.1007/s00268-013-2359-0
State	Published - Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00268-013-2359-0

Cite this

@article{5a9f70334563446b9f9dea94a1e576f0,

title = "SIRT3 expression as a biomarker for better prognosis in gastric cancer",

abstract = "Background: SIRT3 - mitochondrial nicotinamide adenine dinucleotide- dependent deacetylase sirtuin-3 - plays an important role in regulating cell metabolism and carcinogenesis. The role of SIRT3 in gastric cancer has not yet been investigated. Methods: A total of 221 gastric cancer patients who underwent curative surgery were enrolled at the Department of Surgery, Taipei Veterans General Hospital. SIRT3 expression in gastric tissues and tumors were examined in these patients using immunohistochemical staining. Clinicopathologic characteristics and survival were analyzed and compared in gastric cancer patients with or without SIRT3 expression. Results: The 5-year survival rates of patients with or without SIRT3 expression were 51.2 and 39.1 %, respectively (p = 0.005). The 5-year disease-free survival rates of patients with or without SIRT3 expression were 49.6 and 38.0 %, respectively (p = 0.010). Microscopic features showed that there are more poor cell differentiation (p = 0.001), more diffuse-type Lauren's histology (p = 0.018), and more scirrhous-type stromal reactions (p = 0.027) in gastric cancer without SIRT expression. Multivariate analysis with overall survival as an endpoint showed that age (p < 0.001), Lauren's histology (p = 0.007), stromal reaction (p = 0.035), TNM pathologic N category (p < 0.001), and SIRT3 expression (p < 0.001) were significantly correlated with gastric cancer. Conclusions: Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer.",

author = "Huang, {Kuo Hung} and Hsu, {Chia Chi} and Fang, {Wen Liang} and Chi, {Chin Wen} and Sung, {Ming Ta} and Kao, {Hwa Li} and Li, {Anna Fen Yau} and Yin, {Pen Hui} and Yang, {Muh Hwa} and Lee, {Hsin Chen}",

note = "Funding Information: We thank Miss L-J. Dai (Department of Surgery, Taipei Veterans General Hospital) for assistance with the statistics. This study was supported in part by grants from the Taiwan National Science Council (NSC101-2320-B-010-068-MY3, NSC 101-2314-B-075-074, NSC 102-2314-B-075-065), grants from Taipei Veterans General Hospital (V102B-001, V102B-006), and grants from the Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH101-TD-C-111-007, DOH102-TD-C-111-007). ",

year = "2014",

month = apr,

doi = "10.1007/s00268-013-2359-0",

language = "English",

volume = "38",

pages = "910--917",

journal = "World Journal of Surgery",

issn = "0364-2313",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - SIRT3 expression as a biomarker for better prognosis in gastric cancer

AU - Huang, Kuo Hung

AU - Hsu, Chia Chi

AU - Fang, Wen Liang

AU - Chi, Chin Wen

AU - Sung, Ming Ta

AU - Kao, Hwa Li

AU - Li, Anna Fen Yau

AU - Yin, Pen Hui

AU - Yang, Muh Hwa

AU - Lee, Hsin Chen

N1 - Funding Information: We thank Miss L-J. Dai (Department of Surgery, Taipei Veterans General Hospital) for assistance with the statistics. This study was supported in part by grants from the Taiwan National Science Council (NSC101-2320-B-010-068-MY3, NSC 101-2314-B-075-074, NSC 102-2314-B-075-065), grants from Taipei Veterans General Hospital (V102B-001, V102B-006), and grants from the Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH101-TD-C-111-007, DOH102-TD-C-111-007).

PY - 2014/4

Y1 - 2014/4

N2 - Background: SIRT3 - mitochondrial nicotinamide adenine dinucleotide- dependent deacetylase sirtuin-3 - plays an important role in regulating cell metabolism and carcinogenesis. The role of SIRT3 in gastric cancer has not yet been investigated. Methods: A total of 221 gastric cancer patients who underwent curative surgery were enrolled at the Department of Surgery, Taipei Veterans General Hospital. SIRT3 expression in gastric tissues and tumors were examined in these patients using immunohistochemical staining. Clinicopathologic characteristics and survival were analyzed and compared in gastric cancer patients with or without SIRT3 expression. Results: The 5-year survival rates of patients with or without SIRT3 expression were 51.2 and 39.1 %, respectively (p = 0.005). The 5-year disease-free survival rates of patients with or without SIRT3 expression were 49.6 and 38.0 %, respectively (p = 0.010). Microscopic features showed that there are more poor cell differentiation (p = 0.001), more diffuse-type Lauren's histology (p = 0.018), and more scirrhous-type stromal reactions (p = 0.027) in gastric cancer without SIRT expression. Multivariate analysis with overall survival as an endpoint showed that age (p < 0.001), Lauren's histology (p = 0.007), stromal reaction (p = 0.035), TNM pathologic N category (p < 0.001), and SIRT3 expression (p < 0.001) were significantly correlated with gastric cancer. Conclusions: Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer.

AB - Background: SIRT3 - mitochondrial nicotinamide adenine dinucleotide- dependent deacetylase sirtuin-3 - plays an important role in regulating cell metabolism and carcinogenesis. The role of SIRT3 in gastric cancer has not yet been investigated. Methods: A total of 221 gastric cancer patients who underwent curative surgery were enrolled at the Department of Surgery, Taipei Veterans General Hospital. SIRT3 expression in gastric tissues and tumors were examined in these patients using immunohistochemical staining. Clinicopathologic characteristics and survival were analyzed and compared in gastric cancer patients with or without SIRT3 expression. Results: The 5-year survival rates of patients with or without SIRT3 expression were 51.2 and 39.1 %, respectively (p = 0.005). The 5-year disease-free survival rates of patients with or without SIRT3 expression were 49.6 and 38.0 %, respectively (p = 0.010). Microscopic features showed that there are more poor cell differentiation (p = 0.001), more diffuse-type Lauren's histology (p = 0.018), and more scirrhous-type stromal reactions (p = 0.027) in gastric cancer without SIRT expression. Multivariate analysis with overall survival as an endpoint showed that age (p < 0.001), Lauren's histology (p = 0.007), stromal reaction (p = 0.035), TNM pathologic N category (p < 0.001), and SIRT3 expression (p < 0.001) were significantly correlated with gastric cancer. Conclusions: Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84897108383&partnerID=8YFLogxK

U2 - 10.1007/s00268-013-2359-0

DO - 10.1007/s00268-013-2359-0

M3 - Article

C2 - 24322174

AN - SCOPUS:84897108383

SN - 0364-2313

VL - 38

SP - 910

EP - 917

JO - World Journal of Surgery

JF - World Journal of Surgery

IS - 4

ER -

SIRT3 expression as a biomarker for better prognosis in gastric cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this